Company intelligence / Profile preview

SinuSys

Palo Alto, California, United Statesdnb.com ↗

Ownership: Private
Development stage: Commercial

Overview

SinuSys develops minimally invasive medical devices targeting chronic rhinosinusitis and related conditions. Its flagship Vent‑Os Sinus Dilation System uses a low-pressure, self-expanding insert to gently open blocked sinus ostia. Clinical studies show high patency rates at one year with good tolerability. The company also develops drug-delivery spacers such as the Restora steroid-eluting device designed to reduce post-surgical inflammation and scarring. Products are FDA-cleared or CE-marked where applicable; new indications/devices are under study or pending approval.

Therapeutic areas: PulmonologyImmunologyInfectious Diseases
Modalities: Device (Sinus dilation system)Drug-device combination (steroid-eluting spacer)Drug delivery device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on SinuSys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SinuSys.

Explore the full profile